Roche Holding


Looming competition from the east

29/11/19 -"A number of initiatives taken by the Chinese government to strengthen its pharmaceutical sector have started to bear fruit – Biogene’s ‘zanubrutinib’ became the first innovative drug by a Chinese ..."

Pages
90
Language
English
Published on
29/11/19
You may also be interested by these reports :
03/07/20
With CHF13bn ($14bn) annual sales, Roche is a dominant force in the global diagnostics market. Interestingly, in recent years, most diagnostics ...

03/07/20
With increasing demand for Roche’s COVID-19 tests – particularly molecular tests, the annual top-line should benefit by CHF1.5bn. Moreover, taking ...

29/06/20
As many people have been either staying indoors or wearing masks outdoors, there has been a reduction in pollen allergies, which in turn has put ...

26/06/20
Sanofi is developing a COVID-19 vaccine based on the traditional/proven recombinant-platform technology. It has the capability to manufacture 1bn ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO